Merck and Moderna Launch Phase 3 Trial for V940 and KEYTRUDA in Lung Cancer Treatment

Oct 28, 2024, 10:47 AM

Merck and Moderna have initiated a Phase 3 trial to evaluate the efficacy of their investigational individualized neoantigen therapy, V940 (mRNA-4157), in combination with KEYTRUDA (pembrolizumab) and immunotherapy for patients with certain types of non-small cell lung cancer (NSCLC). This trial follows the use of neoadjuvant KEYTRUDA and chemotherapy. The adjuvant mRNA vaccine, a cousin to the COVID-19 vaccines, has entered human trials as a treatment for lung cancer. This marks the third Phase 3 trial for the V940 cancer vaccine and the second specifically targeting early-stage lung cancer.